

Cinzia Solinas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/853090/publications.pdf>

Version: 2024-02-01

46
papers

2,909
citations

236925

25
h-index

265206

42
g-index

46
all docs

46
docs citations

46
times ranked

5162
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 1 | Role of cardiac MRI in the diagnosis of immune checkpoint inhibitor-associated myocarditis. <i>International Journal of Cancer</i> , 2022, 151, 1860-1873. | 5.1 | 19 |
| 2 | Targeting CTLA-4 in cancer: Is it the ideal companion for PD-1 blockade immunotherapy combinations?. <i>International Journal of Cancer</i> , 2021, 149, 31-41. | 5.1 | 23 |
| 3 | Immune Checkpoint Blockade in HER2-Positive Breast Cancer: What Role in Early Disease Setting?. <i>Cancers</i> , 2021, 13, 1655. | 3.7 | 6 |
| 4 | Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 409-424. | 3.8 | 33 |
| 5 | Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. <i>Targeted Oncology</i> , 2021, 16, 553-568. | 3.6 | 13 |
| 6 | A review of immune checkpoint blockade in breast cancer. <i>Seminars in Oncology</i> , 2021, 48, 208-225. | 2.2 | 11 |
| 7 | Functional Th1-oriented T follicular helper cells that infiltrate human breast cancer promote effective adaptive immunity. <i>Journal of Clinical Investigation</i> , 2021, 131, . | 8.2 | 70 |
| 8 | Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review. <i>Translational Oncology</i> , 2020, 13, 410-422. | 3.7 | 52 |
| 9 | Breast cancer vaccines: Heeding the lessons of the past to guide a path forward. <i>Cancer Treatment Reviews</i> , 2020, 84, 101947. | 7.7 | 35 |
| 10 | Burning Questions in the Oncofertility Counseling of Young Breast Cancer Patients. <i>Breast Cancer: Basic and Clinical Research</i> , 2020, 14, 117822342095417. | 1.1 | 15 |
| 11 | Radiomics and radiomics in cancer immunotherapy: a guide for clinicians. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 154, 103068. | 4.4 | 26 |
| 12 | Excision Repair Cross Complementation Group 1 Single Nucleotide Polymorphisms and Nivolumab in Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1167. | 2.8 | 8 |
| 13 | A critical evaluation of glucocorticoids in the management of severe COVID-19. <i>Cytokine and Growth Factor Reviews</i> , 2020, 54, 8-23. | 7.2 | 77 |
| 14 | Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer?. <i>Translational Oncology</i> , 2020, 13, 100811. | 3.7 | 46 |
| 15 | Immune Checkpoint Inhibitor-Induced Pancreatic Injury: Imaging Findings and Literature Review. <i>Targeted Oncology</i> , 2020, 15, 25-35. | 3.6 | 25 |
| 16 | The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy. <i>ESMO Open</i> , 2020, 5, e000544. | 4.5 | 95 |
| 17 | Gender-specific aspects related to type of fertility preservation strategies and access to fertility care. <i>ESMO Open</i> , 2020, 5, e000771. | 4.5 | 13 |
| 18 | LAG3: The Biological Processes That Motivate Targeting This Immune Checkpoint Molecule in Human Cancer. <i>Cancers</i> , 2019, 11, 1213. | 3.7 | 75 |

| # | ARTICLE | IF | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 19 | Targeting PD-1 in cancer: Biological insights with a focus on breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 142, 35-43. | 4.4 | 18 |
| 20 | Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features. <i>Cancers</i> , 2019, 11, 305. | 3.7 | 51 |
| 21 | BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer. <i>Cancer Letters</i> , 2019, 450, 88-97. | 7.2 | 33 |
| 22 | Significance of TIM3 expression in cancer: From biology to the clinic. <i>Seminars in Oncology</i> , 2019, 46, 372-379. | 2.2 | 49 |
| 23 | FOXP1 negatively regulates tumor infiltrating lymphocyte migration in human breast cancer. <i>EBioMedicine</i> , 2019, 39, 226-238. | 6.1 | 36 |
| 24 | Tumor-infiltrating B cells signal functional humoral immune responses in breast cancer. <i>JCI Insight</i> , 2019, 4, . | 5.0 | 182 |
| 25 | Abstract 3132: Immune regulatory gene expression and clinical outcome in the NeoALTTO trial. , 2019, , . | | 0 |
| 26 | The Abscopal Effect in the Era of Cancer Immunotherapy: a Spontaneous Synergism Boosting Anti-tumor Immunity?. <i>Targeted Oncology</i> , 2018, 13, 113-123. | 3.6 | 26 |
| 27 | Radiological evaluation of response to immunotherapy in brain tumors: Where are we now and where are we going?. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 126, 135-144. | 4.4 | 14 |
| 28 | Cancer immunotherapy-associated hypophysitis. <i>Seminars in Oncology</i> , 2018, 45, 181-186. | 2.2 | 47 |
| 29 | Quantifying Tertiary Lymphoid Structure-Associated Genes in Formalin-Fixed Paraffin-Embedded Breast Cancer Tissues. <i>Methods in Molecular Biology</i> , 2018, 1845, 139-157. | 0.9 | 6 |
| 30 | Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning. <i>Seminars in Cancer Biology</i> , 2018, 52, 151-157. | 9.6 | 108 |
| 31 | Abstract 4689: Immune functions and regulation of follicular helper CD4+CXCR5+T cells in human breast cancer. , 2018, , . | | 0 |
| 32 | Abstract 1624: Reliability of immune biomarker assessment in breast cancer: A report on interobserver variability from studies at a single institution. <i>Cancer Research</i> , 2018, 78, 1624-1624. | 0.9 | 3 |
| 33 | Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 110, 106-116. | 4.4 | 33 |
| 34 | The immune infiltrate in prostate, bladder and testicular tumors: An old friend for new challenges. <i>Cancer Treatment Reviews</i> , 2017, 53, 138-145. | 7.7 | 20 |
| 35 | Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2017, 18, 4. | 3.0 | 17 |
| 36 | Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials. <i>Cancer Treatment Reviews</i> , 2017, 57, 8-15. | 7.7 | 75 |

| # | ARTICLE | IF | CITATIONS |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 37 | Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer. <i>Oncolmmunology</i> , 2017, 6, e1257452. | 4.6 | 169 |
| 38 | Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 120, 13-21. | 4.4 | 56 |
| 39 | Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: Current state of the art. <i>Breast</i> , 2017, 35, 142-150. | 2.2 | 87 |
| 40 | Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. <i>Advances in Anatomic Pathology</i> , 2017, 24, 311-335. | 4.3 | 530 |
| 41 | Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Anatomic Pathology</i> , 2017, 24, 235-251. | 4.3 | 469 |
| 42 | Targeting immune checkpoints in breast cancer: an update of early results. <i>ESMO Open</i> , 2017, 2, e000255. | 4.5 | 118 |
| 43 | Adjuvant trastuzumab: a 10-year overview of its benefit. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 61-74. | 2.4 | 40 |
| 44 | Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer. <i>Frontiers in Immunology</i> , 2017, 8, 1412. | 4.8 | 80 |
| 45 | Abstract A62: Investigating the role of follicular helper T cells, B cells and CXCL13 in breast cancer-associated tertiary lymphoid structures. , 2017, , . | | 0 |
| 46 | Transcription Factors and Checkpoint Inhibitor Expression with Age: Markers of Immunosenescence?. <i>Blood</i> , 2016, 128, 5983-5983. | 1.4 | 0 |